PERFADEX® and STEEN Solution™ approved in Russia

XVIVO Perfusion has obtained approval in Russia for marketing and clinical use
of PERFADEX® and STEEN Solution™.
Russia’s Federal Service for Supervision on Health Care has approved PERFADEX®
and STEEN Solution™ for lung transplantation. This means that PERFADEX® and
STEEN Solution™ may be sold for clinical use in Russia.

Russia is not a large market today, but there is a great need for more lung
transplants to be performed in the region. This registration allows clinics in
Russia to gain access to PERFADEX®, which is adapted to lung preservation, and
to be able to evaluate the quality of lungs using STEEN Solution™ and Ex Vivo
Lung Perfusion (EVLP).

“The registration of PERFADEX® and STEEN Solution™ in Russia increases the
accessibility of lung transplant products in this region and is a step in the
right direction towards our vision that “No-one should need to die waiting for a
new organ”. It is also in line with our long-term focus on future growth
markets,” says Magnus Nilsson, CEO of XVIVO Perfusion.

February 16, 2016
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on February 16, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com